Medtronic (NYSE:MDT) posted its quarterly earnings results on Thursday. The medical technology company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.28 by ($0.70), MarketWatch Earnings reports. Medtronic had a return on equity of 12.17% and a net margin of 16.56%. The firm had revenue of $6 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period last year, the company posted $1.54 earnings per share. The firm’s quarterly revenue was down 26.4% compared to the same quarter last year.
NYSE:MDT opened at $94.72 on Friday. The company has a market capitalization of $127.87 billion, a P/E ratio of 20.79, a P/E/G ratio of 2.57 and a beta of 0.69. The business has a fifty day simple moving average of $96.70 and a two-hundred day simple moving average of $105.81. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.13 and a quick ratio of 2.28. Medtronic has a 1 year low of $72.13 and a 1 year high of $122.15.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a dividend of $0.58 per share. This represents a $2.32 annualized dividend and a yield of 2.45%. This is a positive change from Medtronic’s previous quarterly dividend of $0.54. The ex-dividend date is Thursday, June 25th. Medtronic’s dividend payout ratio is 47.06%.
A number of research analysts recently weighed in on MDT shares. Sanford C. Bernstein reaffirmed a “hold” rating and set a $112.00 price target on shares of Medtronic in a research note on Thursday, April 23rd. Citigroup dropped their price target on Medtronic from $124.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, March 27th. ValuEngine lowered Medtronic from a “hold” rating to a “sell” rating in a report on Friday, February 28th. Deutsche Bank decreased their price objective on Medtronic from $123.00 to $118.00 and set a “buy” rating for the company in a report on Friday. Finally, Oppenheimer decreased their price objective on Medtronic from $131.00 to $112.00 and set an “outperform” rating for the company in a report on Friday. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $115.31.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Further Reading: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.